Pfizer: CHMP Adopts Positive Opinion for BAVENCIO Plus Axitinib for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
September 20, 2019
September 20, 2019
NEW YORK, Sept. 20 -- Pfizer, a pharmaceutical company, issued the following news release:
* * *
- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib/1
- Decision by the European Commission anticipated in fourth quarter of 2019
* * *
Rockland, MA and New York, US - EMD Serono, the biopharmaceutical business of Merck KGa . . .
* * *
- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib/1
- Decision by the European Commission anticipated in fourth quarter of 2019
* * *
Rockland, MA and New York, US - EMD Serono, the biopharmaceutical business of Merck KGa . . .